{"product_id":"phobriga-90-brigatinib","title":"LETEDX (Letermovir)","description":"\u003ch2\u003eAbout Letermovir\u003c\/h2\u003e\u003cp\u003eLetermovir  is an antiviral drug for the treatment of cytomegalovirus (CMV) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections.\u003c\/p\u003e\u003ch2\u003eAdult\u003c\/h2\u003e\u003ch3\u003eCytomegalovirus Infection Prophylaxis in HSCT\u003c\/h3\u003e\u003cp\u003eIndicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)\u003c\/p\u003e\u003cp\u003e480 mg PO\/IV (one 480 mg tab or two 240 mg tabs) qDay; may use four 120 mg packets of oral pellets qDay for patient who cannot swallow tablets; initiate between Day 0 and Day 28 posttransplantation (before or after engraftment) and continue through Day 100\u003c\/p\u003e\u003cp\u003eMay continue through Day 200 post HSCT for patients at risk for late CMV infection and disease\u003c\/p\u003e\u003ch3\u003eCytomegalovirus Disease Prophylaxis in Kidney Transplant Recipients\u003c\/h3\u003e\u003cp\u003eIndicated for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (donor CMV seropositive\/recipient CMV seronegative [D+\/R-])\u003c\/p\u003e\u003cp\u003e480 mg PO\/IV (one 480 mg tab or two 240 mg tabs) qDay; may use four 120 mg packets of oral pellets qDay; initiate between Day 0 and Day 7 post-transplant and continue through Day 200 post-transplant\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eCoadministration with cyclosporine\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eDecrease letermovir dose to 240 mg\/day if coadministered with cyclosporine (monitor cyclosporine levels)\u003c\/li\u003e\n\u003cli\u003eIf cyclosporine initiated after letermovir, decrease the next letermovir dose to 240 mg\/day\u003c\/li\u003e\n\u003cli\u003eIf cyclosporine discontinued after starting letermovir, increase the next letermovir dose to 480 mg\/day\u003c\/li\u003e\n\u003cli\u003eIf cyclosporine dosing is interrupted because of high cyclosporine levels, no dose adjustment of letermovir is needed\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl \u0026gt;10 mL\/min: No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eCrCl ≤10 mL\/min or patient on dialysis: Data are insufficient to make dosing recommendations\u003c\/li\u003e\n\u003cli\u003eHydroxypropyl betadex (IV vehicle) may accumulate if CrCl \u0026lt;50 mL\/min; closely monitor serum creatinine levels in patients receiving IV letermovir\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh A or B): No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eFollowing prophylaxis completion, monitoring for CMV reactivation recommended\u003c\/p\u003e\u003cp\u003eUse IV only in patients unable to take oral therapy; switch to oral administration as soon as feasible\u003c\/p\u003e\u003cp\u003eTablet and injection may be used interchangeably at the discretion of the physician; no dosage adjustment is necessary when switching formulations\u003c\/p\u003e\u003ch2\u003ePediatric\u003c\/h2\u003e\u003ch3\u003eCytomegalovirus infection prophylaxis in HSCT\u003c\/h3\u003e\u003cp\u003eIndicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)\u003c\/p\u003e\u003ch4\u003e\u0026gt;12 years\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\u0026gt;=30 kg: 480 mg (one 480 mg tab or two 240 mg tabs) PO\/IV qDay; may use four 120 mg packets of oral pellets qDay for patient who cannot swallow tablets\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u0026gt;=6 years:\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e15-30 kg: 240 mg (one 240 mg tab or two 120 mg packets o) PO qDay; may use four 120 mg packets of oral pellets qDay or 120 mg IV qDay\u003c\/li\u003e\n\u003cli\u003e7.5 to \u0026lt; 30 kg: tablets not recommended; 120 mg packets o) PO qDay; may use one 120 mg packets of oral pellets qDay or 60 mg IV qDay\u003c\/li\u003e\n\u003cli\u003e6 to \u0026lt;7.5 kg: tablets not recommended; four 20 mg packets of oral pellets PO qDay or 40 mg IV qDay\u003c\/li\u003e\n\u003cli\u003eInitiate between Day 0 and Day 28 posttransplantation (before or after engraftment) and continue through Day 100\u003c\/li\u003e\n\u003cli\u003eMay continue through Day 200 post HSCT for patients at risk for late CMV infection and disease\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eCytomegalovirus disease prophylaxis in kidney transplant recipients\u003c\/h3\u003e\u003cp\u003eIndicated for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (donor CMV seropositive\/recipient CMV seronegative [D+\/R-])\u003c\/p\u003e\u003ch4\u003e\u0026gt;12 years\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\u0026gt;=30 kg: 480 mg (one 480 mg tab or two 240 mg tabs) PO\/IV qDay; may use four 120 mg packets of oral pellets qDay for patient who cannot swallow tablets\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u0026gt;=6 years:\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e15-30 kg: 240 mg (one 240 mg tab or two 120 mg packets o) PO qDay; may use four 120 mg packets of oral pellets qDay or 120 mg IV qDay\u003c\/li\u003e\n\u003cli\u003e7.5 to \u0026lt; 30 kg: tablets not recommended; 120 mg packets o) PO qDay; may use one 120 mg packets of oral pellets qDay or 60 mg IV qDay\u003c\/li\u003e\n\u003cli\u003e6 to \u0026lt;7.5 kg: tablets not recommended; four 20 mg packets of oral pellets PO qDay or 40 mg IV qDay\u003c\/li\u003e\n\u003cli\u003eInitiate between Day 0 and Day 7 post-transplant and continue through Day 200 post-transplant\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage modifications\u003c\/h3\u003e\u003ch4\u003eCoadministration with cyclosporine in HSCT patients (\u0026gt;=12 years and \u0026gt;=30 kg) and kidney transplant (\u0026gt;=12 years and \u0026gt;=40 kg)\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eDecrease letermovir dose to 240 mg\/day if coadministered with cyclosporine (monitor cyclosporine levels)\u003c\/li\u003e\n\u003cli\u003eIf cyclosporine initiated after letermovir, decrease the next letermovir dose to 240 mg\/day\u003c\/li\u003e\n\u003cli\u003eIf cyclosporine discontinued after starting letermovir, increase the next letermovir dose to 480 mg\/day\u003c\/li\u003e\n\u003cli\u003eIf cyclosporine dosing is interrupted because of high cyclosporine levels, no dose adjustment of letermovir is needed\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCo-administered with cyclosporine in HSCT recipients 6 Months to \u0026lt;12 years or \u0026gt;=12 Years and \u0026lt;30 kg\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e15 to \u0026lt;30 kg: Tablets not recommended; one 120 mg packet of oral pellets PO qDay or 120 mg IV qDay\u003c\/li\u003e\n\u003cli\u003e7.5 to \u0026lt; 15 kg: Tablets not recommended; three 20 mg packets of oral pellets PO qDay ot 60 mg IV qDay\u003c\/li\u003e\n\u003cli\u003e6 to 7.5 kg: Tablets not recommended; two 20 mg packets of oral pellets or 40 mg IV qDay\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl \u0026gt;10 mL\/min: No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eCrCl ≤10 mL\/min or patient on dialysis: Data are insufficient to make dosing recommendations\u003c\/li\u003e\n\u003cli\u003eHydroxypropyl betadex (IV vehicle) may accumulate if CrCl \u0026lt;50 mL\/min; closely monitor serum creatinine levels in patients receiving IV letermovir\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing considerations\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFollowing prophylaxis completion, monitoring for CMV reactivation recommended\u003c\/li\u003e\n\u003cli\u003eUse IV only in patients unable to take oral therapy; switch to oral administration as soon as feasible\u003c\/li\u003e\n\u003cli\u003eTablet and injection may be used interchangeably at the discretion of the physician; no dosage adjustment is necessary when switching formulations\u003c\/li\u003e\n\u003cli\u003eDosage adjustment may be necessary for pediatric patients \u0026lt;12 years of age when switching between oral and intravenous formulations\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797945643051,"sku":"RL3020240925","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-09-2031.jpg?v=1787022059","url":"https:\/\/xomeds.com\/products\/phobriga-90-brigatinib","provider":"XOMEDS","version":"1.0","type":"link"}